ÂÜÀòÂÒÂ×

Veenu Aishwarya is an innovator and a result-oriented biotechnology entrepreneur. He received his biomedical research training while working as a visiting scholar at the Perelman School of Medicine, University of Pennsylvania in Philadelphia.

At AUM LifeTech, Mr. Aishwarya has been leading, developing, and strategizing applications of AUM LifeTech’s proprietary next-generation RNA Silencing FANA Antisense Oligonucleotide Technology (FANA ASO) for personalized medicine. Mr. Aishwarya has over 15 years of experience in the discovery, optimization, and development of nucleic acids therapeutics. Mr. Aishwarya has invented several new medical applications of FANA ASO technology including the use of FANAs for cancer immunotherapy. Mr. Aishwarya has filed several patents on the use of FANA ASO technology for multiple research and therapeutic applications. Several of his inventions and products have shown significant commercial value in biomedical research and therapeutic development. Most recently, under Mr. Aishwarya’s leadership, AUM LifeTech was selected by the NIH as a part of the BIO Innovation Zone 2021. The Innovation Zone showcases NIH-funded small businesses and their cutting-edge healthcare technologies.

In 2017, Mr. Aishwarya was recognized as Millennials to Watch in Life Sciences by the Philadelphia Business Journal. In 2018, he was recognized as one of the 2018 Health Care Innovators by the Philadelphia Business Journal. In 2019, Mr. Aishwarya was recognized as the Forty under 40 business leaders by the Philadelphia Business Journal. He is also an invited member of the Philadelphia Leadership Trust and recognized as a Business Influencer by the Philadelphia Business Journal.